Stockscreener 앱 받기
2.89
5.09%
0.14
시간 외 거래:
2.93
0.04
+1.38%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Cabaletta Bio (CABA) Reports Promising Phase 1/2 Data Amid Unpro - GuruFocus
668,563 Shares in Cabaletta Bio, Inc. $CABA Bought by GSA Capital Partners LLP - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cormorant Asset Management (CABA) discloses 10M-share Cabaletta Bio stake - Stock Titan
CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00 - GuruFocus
Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - MarketBeat
Cabaletta Bio (CABA): T. Rowe Price reports 11.6% common stock stake - Stock Titan
Caballeta Bio (CABA) stake: Bain Capital Life Sciences reports 9.99% position - Stock Titan
Cabaletta Bio Inc (NASDAQ: CABA) Share Price, CABA Stock News, CABA Share Price & Updates - Kalkine
Cabaletta Bio Releases Q2 2026 Financial Results - news.alphastreet.com
Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress - Investing.com
Why is Cabaletta Bio stock sliding today? By Investing.com - Investing.com Australia
Why is Cabaletta Bio stock sliding today? - Investing.com
Cabaletta Bio Reports Q2 2026 Form 10-Q Highlighting Going Concern and Funding Challenges - Kalkine Media
Cabaletta Bio, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio (CABA) Q2 Earnings Beat Expectations; Market Focuses on Growth Potential Despite Losses - GuruFocus
Form 8K Cabaletta Bio Inc For: 13 August By Investing.com - Investing.com Nigeria
Cabaletta Bio Q2 net loss widens as R&D costs rise - TradingView
Cabaletta Bio, Inc. 2Q 2026: Net loss $(51.0)M, EPS $(0.34) — 10-Q Summary - TradingView
Cabaletta Bio (CABA) lifts cash to $225M while advancing rese-cel toward BLA - Stock Titan
Cabaletta Bio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio Reports $51.0 Million Second-Quarter Net Loss - Quiver Quantitative
Cabaletta Bio (NASDAQ: CABA) lifts cash to $225M while advancing CAR-T trials - Stock Titan
Cabaletta Bio reports Q2 2026 net loss of $51.0M; cash position $225.1M supports operations into mid-2027 - TradingView
Cabaletta Bio Inc (CABA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Adage Capital discloses 8.43% Cabaletta Bio (CABA) stake including warrant shares - Stock Titan
Cabaletta Bio (CABA): Norges Bank reports 5.382% ownership of 8.78M shares - Stock Titan
Cabaletta Bio, Inc. expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Cabaletta Bio, Inc. Stock 12‑Month Price Target Raised to $14.71, Implies 427% Upside - TradingView
Renaissance Technologies LLC Acquires 514,080 Shares of Cabaletta Bio, Inc. $CABA - MarketBeat
CABA Q2'26 Earnings: EPS estimate is (0.37) USD - TradingView
QTTB Stock Price and Chart — NASDAQ:QTTB - TradingView
Vanguard Capital Management (CABA) discloses 8.30M-share passive stake in Cabaletta Bio - Stock Titan
CABA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
CABA|Cabaletta Bio Inc|Price:2.720|Chg%:+0.030 - TradingKey
BlackRock (CABA) discloses 9.6M Cabaletta Bio shares under sole control - Stock Titan
Cabaletta Bio Inc (CABA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cabaletta Bio Inc (CABA) Cash Flow - TradingKey
Cabaletta Bio Inc (CABA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cabaletta Bio Inc (CABA) Institutional Confidence - TradingKey
Cabaletta Bio Inc (CABA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cabaletta Bio Market Sentiment - Benzinga España
Cabaletta Bio Inc (CABA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cabaletta Bio Inc (CABA) Income Statement - TradingKey
Cabaletta Bio Inc (CABA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CABA|Cabaletta Bio Inc|Price:2.690|Chg%:-0.030 - TradingKey
Cabaletta Bio Inc (CABA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cabaletta Bio, Inc. Revenue Breakdown – NASDAQ:CABA - TradingView
Cabaletta Bio (CABA) sees Millennium group report 2.07M-share, 1.3% ownership stake - Stock Titan
Cabaletta Bio (CABA) Guggenheim Securities Inaugural Healthcare Innovation Conference summary - Quartr
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Cabaletta Bio (CABA) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr
ETFs Investing in Cabaletta Bio, Inc. Stocks - TradingView
Cabaletta Bio Insider Buyers Net US$56k Despite 14% Stock Decline - 富途牛牛
Cabaletta Bio : CABA - 24/7 Wall St.
1.80%
1.77%
자본화:
|
볼륨(24시간):